MX2019000514A - Anticuerpos de tgfb, métodos, y usos. - Google Patents

Anticuerpos de tgfb, métodos, y usos.

Info

Publication number
MX2019000514A
MX2019000514A MX2019000514A MX2019000514A MX2019000514A MX 2019000514 A MX2019000514 A MX 2019000514A MX 2019000514 A MX2019000514 A MX 2019000514A MX 2019000514 A MX2019000514 A MX 2019000514A MX 2019000514 A MX2019000514 A MX 2019000514A
Authority
MX
Mexico
Prior art keywords
protgfb1
selective antibodies
antigen
binding fragments
garp complex
Prior art date
Application number
MX2019000514A
Other languages
English (en)
Inventor
J Carven Gregory
Schurpf Thomas
Turner Katherine
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2019000514A publication Critical patent/MX2019000514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se pueden usar anticuerpos selectivos del complejo GARP-proTGFß1, polinucleotidos capaces de codificar los anticuerpos o fragmentos de union al antigeno selectivos del complejo GARP-proTGFß1, celulas que expresan anticuerpos o fragmentos de union al antigeno selectivos del complejo GARP-proTGFß1, asi como vectores asociados y anticuerpos y fragmentos de union al antigeno selectivos del complejo GARP-proTGFß1 marcados detectables para mejorar una respuesta inmune en un sujeto, por ejemplo, contra un cancer.
MX2019000514A 2016-07-14 2017-07-14 Anticuerpos de tgfb, métodos, y usos. MX2019000514A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05
PCT/US2017/042162 WO2018013939A1 (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Publications (1)

Publication Number Publication Date
MX2019000514A true MX2019000514A (es) 2019-07-12

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000514A MX2019000514A (es) 2016-07-14 2017-07-14 Anticuerpos de tgfb, métodos, y usos.

Country Status (13)

Country Link
US (2) US20190292254A1 (es)
EP (1) EP3484499A4 (es)
JP (2) JP7128801B2 (es)
KR (1) KR102577551B1 (es)
CN (1) CN110049773A (es)
AU (1) AU2017294772B2 (es)
BR (1) BR112019000621A2 (es)
CA (1) CA3030862A1 (es)
IL (1) IL264161A (es)
MA (1) MA45690A (es)
MX (1) MX2019000514A (es)
SG (1) SG11201900200XA (es)
WO (1) WO2018013939A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102362609B1 (ko) 2013-08-01 2022-02-11 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
DK3365368T3 (da) 2016-03-11 2023-06-26 Scholar Rock Inc Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
TW202019957A (zh) * 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
RS62914B1 (sr) 2018-07-11 2022-03-31 Scholar Rock Inc Izoform selektivni inhibitori tgfbeta1 i njihova upotreba
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
KR20210121174A (ko) 2019-01-30 2021-10-07 스칼러 락, 인크. TGFβ의 LTBP 복합체-특이적 억제제 및 그의 용도
CA3155172A1 (en) * 2019-10-25 2021-04-29 Shinko HAYASHI Combination of anti-garp antibody and immunomodulator
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20240301073A1 (en) 2021-07-14 2024-09-12 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
KR20240045310A (ko) * 2021-09-30 2024-04-05 베타 파머수티컬 컴퍼니 리미티드 이중특이성 항체 및 그 응용
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101155294B1 (ko) * 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP2468881A3 (en) * 2005-07-21 2012-08-15 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN103003424B (zh) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
MX367042B (es) * 2012-10-02 2019-08-02 Bristol Myers Squibb Co Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
JP2016521283A (ja) * 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
KR102362609B1 (ko) * 2013-08-01 2022-02-11 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
WO2015171691A2 (en) * 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016164468A2 (en) * 2015-04-07 2016-10-13 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to adamts13 and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體

Also Published As

Publication number Publication date
EP3484499A4 (en) 2020-05-13
US20210277100A1 (en) 2021-09-09
IL264161A (en) 2019-02-28
AU2017294772A1 (en) 2019-01-31
BR112019000621A2 (pt) 2019-04-24
KR20190034560A (ko) 2019-04-02
EP3484499A1 (en) 2019-05-22
WO2018013939A1 (en) 2018-01-18
US20190292254A1 (en) 2019-09-26
SG11201900200XA (en) 2019-02-27
AU2017294772B2 (en) 2024-05-02
JP2022153406A (ja) 2022-10-12
JP7128801B2 (ja) 2022-08-31
JP2019524094A (ja) 2019-09-05
MA45690A (fr) 2019-05-22
KR102577551B1 (ko) 2023-09-11
CN110049773A (zh) 2019-07-23
CA3030862A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
MX2019000514A (es) Anticuerpos de tgfb, métodos, y usos.
PH12018501902A1 (en) Gitr antibodies, methods, and uses
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
PH12016502505A1 (en) Bispecific t cell activating antigen binding molecules
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MY184889A (en) T cell activating bispecific antigen binding molecules
MX2019007021A (es) Anticuerpos il-11ra.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
CR20170079A (es) Agentes de unión a cd123 y usos de estos
SG10201909716RA (en) Modified j-chain
MX2017009937A (es) Cepas fungicas y metodos de uso.
MX2021006732A (es) Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MY188405A (en) Anti-cd154 antibodies and methods of using them
AU2015279552A8 (en) Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
PH12016500826A1 (en) Anti-ccl17 antibodies
SG10201803094QA (en) Monoliths with attached recognition compounds, arrays thereof and uses thereof
MY191596A (en) Igf-1r antibody and its use for the diagnosis of cancer
EA201990289A1 (ru) АНТИТЕЛА К TGFβ, СПОСОБЫ И ПРИМЕНЕНИЯ
EA201891998A1 (ru) Антитела к gitr, способы и применение